With 92109.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.53 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.11 whereas the lowest price it dropped to was $2.02. The 52-week range on QNCX shows that it touched its highest point at $2.45 and its lowest point at $0.51 during that stretch. It currently has a 1-year price target of $9.67. Beta for the stock currently stands at 0.73.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QNCX was up-trending over the past week, with a rise of 10.87%, but this was up by 72.88% over a month. Three-month performance surged to 194.24% while six-month performance rose 145.10%. The stock gained 122.51% in the past year, while it has gained 94.29% so far this year. EPS is expected to grow by 18.30% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -12.64%.
Float and Shares Shorts:
At present, 42.97 million QNCX shares are outstanding with a float of 32.62 million shares on hand for trading. On 2024-10-31, short shares totaled 2.35 million, which was 542.0 higher than short shares on 1727654400. In addition to Dr. Dirk Thye M.D. as the firm’s CEO, Chief Medical Officer & Director, Dr. Charles S. Ryan J.D., Ph.D. serves as its President.
Institutional Ownership:
Through their ownership of 0.25533 of QNCX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, QNCX reported revenue of $0.0 and operating income of -$8546000.0. The EBITDA in the recently reported quarter was -$11143000.0 and diluted EPS was -$0.13.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With QNCX analysts setting a high price target of 12.0 and a low target of 6.0, the average target price over the next 12 months is 9.0. Based on these targets, QNCX could surge 488.24% to reach the target high and rise by 194.12% to reach the target low. Reaching the average price target will result in a growth of 341.18% from current levels.
Analysts have provided yearly estimates in a range of -$1.22 being high and -$1.22 being low. For QNCX, this leads to a yearly average estimate of -$1.22. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
